Idiopathic and post-infective bronchiectasis show no clinically important differences in outcomes or airway inflammatory profiles
james hill (Dundee, United Kingdom), James Hill, Duncan Renton, Hani Abo-Leyah, Megan Crichton, Simon Finch, Thomas Fardon, James Chalmers
|   |
Impact of co-morbidities on disease severity and risk of mortality in non-cystic fibrosis bronchiectasis
Melissa McDonnell (Galway, Ireland), Melissa McDonnell, Thomas Fardon, Robert Rutherford, James Chalmers
| |
Determinants and assessment of excess cardiovascular risk in bronchiectasis
Aarash Saleh (London, United Kingdom), Aarash Saleh, Bessie Kwok, Jeremy Brown, John Hurst
|  |
Thrombocytosis is associated with disease severity and outcomes in stable bronchiectasis
Duncan Renton (Dundee, United Kingdom), Duncan Renton, James Hill, Hani Abo-Leyeh, Simon Finch, Megan Crichton, Thomas Fardon, Alison Dicker, James Chalmers
| |
Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort
Philip Mitchelmore (Exeter, United Kingdom), Philip Mitchelmore, Louise Anning, Victoria Carnell, Sarah Jephcote, Pia Charters, Tim Crowe, Christopher Dean, Anna Lowdon, Christopher Sheldon, Nicholas Withers
| |
A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis
Simon Finch (Dunfermline, United Kingdom), Simon Finch, Tom Fardon, Melissa Friel, James Chalmers
| |
Non-CF bronchiectasis impact on hospital admissions – Need to change the paradigm
João Henrique Cordeiro da Costa (Baguim do Monte - Gondomar, Portugal), João Cordeiro da Costa, Regina Monteiro
| |
Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group
Stefano Aliberti (Milan, Italy), Stefano Aliberti, Eva Polverino, Anthony De Soyza, Michael R. Loebinger, Rosario Menendez, Felix C. Ringshausen, Montserrat Vendrell, James D. Chalmers
| |